Radmila Ajduković

FC RIIIA and FC RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma

Zdravko Mitrović, Igor Aurer, Ivo Radman et al. · Haematologica · 2007 · 58 citations · Full text

Medicine, Hematology, Oncology +14

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab

Ivana Ilić, Zdravko Mitrović, Igor Aurer et al. · International Journal of Hematology · 2009 · 30 citations

Medicine, Oncology, Chemotherapy +15

CD43 Expression Is an Adverse Prognostic Factor in Diffuse Large B-Cell Lymphoma

Zdravko Mitrović, Ivana Ilić, Marin Nola et al. · Clinical Lymphoma & Myeloma · 2009 · 25 citations

Medicine, Oncology, Pathology +12

Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status

Maruška Marušić Vrsalović, Vlatko Pejša, Tajana Štoos Veić et al. · Cancer Biology & Therapy · 2007 · 24 citations · Full text

Medicine, Genetics, Hematology +14

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients

Vlatko Pejša, Željko Prka, Marko Lucijanić et al. · Croatian Medical Journal · 2017 · 16 citations · Full text

Medicine, Hematology, Oncology +15